Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Patients with corticobasal degeneration can present with several different clinical syndromes, making ante-mortem diagnosis a challenge. Corticobasal syndrome is the clinical phenotype originally described for corticobasal degeneration, characterized by asymmetric rigidity and apraxia, cortical sensory deficits, dystonia and myoclonus. Some patients do not develop these features, but instead have clinical features consistent with the Richardson syndrome presentation of progressive supranuclear palsy, characterized by postural instability, early unexplained falls, vertical supranuclear gaze palsy, symmetric motor disability and dysphagia. The aim of this study was to identify differences in corticobasal degeneration presenting with corticobasal syndrome (n = 11) or Richardson syndrome (n = 15) with respect to demographic, clinical and neuropathological features. Corticobasal degeneration cases were also compared with patients with pathologically proven progressive supranuclear palsy with Richardson syndrome (n = 15). Cases with corticobasal degeneration, regardless of presentation, shared histopathological and tau biochemical characteristics, but they had differing densities of tau pathology in neuroanatomical regions that correlated with their clinical presentation. In particular, those with corticobasal syndrome had greater tau pathology in the primary motor and somatosensory cortices and putamen, while those with Richardson syndrome had greater tau pathology in limbic and hindbrain structures. Compared with progressive supranuclear palsy, patients with corticobasal degeneration and Richardson syndrome had less neuronal loss in the subthalamic nucleus, but more severe neuronal loss in the medial substantia nigra and greater atrophy of the anterior corpus callosum. Clinically, they had more cognitive impairment and frontal behavioural dysfunction. The results suggest that Richardson syndrome can be a clinicopathological presentation of corticobasal degeneration. Atrophy of anterior corpus callosum may be a potential neuroimaging marker to differentiate corticobasal degeneration from progressive supranuclear palsy in patients with Richardson syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538 · cited 6×
“(2008) rather than NINDS-SPSP research criteria for probable progressive supranuclear palsy (Litvan et al., 1996).”
BackgroundMethodResultInfluentialSelf-citationNeuropathological assessment of Parkinson’s disease: refining the diagnostic criteria
Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70238-8 · Cited by 972 · cited 3×
“Both patients with PSP-RS and CBD-RS had severe neuronal loss in the ventrolateral cell groups of the substantia nigra, which is known to correlate with extrapyramidal features in parkinsonism (Fearnley and Lees, 1991; Dickson et al., 2009).”
BackgroundSelf-citationOffice of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
Dickson, D. W., Bergeron, C., Chin, S. S., Duyckaerts, C., Horoupian, D., Ikeda, K., Jellinger, K., Lantos, P. L., Lippa, C. F., Mirra, S. S., et al. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.935 · Cited by 724 · cited 4×
“Pathological assessment and diagnosis was according to research criteria for progressive supranuclear palsy and corticobasal degeneration as previously described (Hauw et al., 1994; Dickson et al., 2002).”
BackgroundMethodInfluentialSelf-citationThe evolution and pathology of frontotemporal dementia
Kertesz, A., McMonagle, P., Blair, M., Davidson, W., & Munoz, D. G. (2005) · Brain · doi:10.1093/brain/awh598 · Cited by 609
Pathologic heterogeneity in clinically diagnosed corticobasal degeneration
Boeve, B. F., Maraganore, D. M., Parisi, J. E., Ahlskog, J. E., Graff-Radford, N., Caselli, R. J., Dickson, D. W., Kokmen, E., & Petersen, R. C. (1999) · Neurology · doi:10.1212/wnl.53.4.795 · Cited by 417
Self-citationDoes corticobasal degeneration exist? A clinicopathological re-evaluation
Ling, H., O'Sullivan, S. S., Holton, J. L., Revesz, T., Massey, L. A., Williams, D. R., Paviour, D. C., & Lees, A. J. (2010) · Brain · doi:10.1093/brain/awq123 · Cited by 394
Boxer, A. L., Geschwind, M. D., Belfor, N., Gorno-Tempini, M. L., Schauer, G. F., Miller, B. L., Weiner, M. W., & Rosen, H. J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.81 · Cited by 337 · cited 1×
“…for clinical heterogeneity The anatomical distribution of brain atrophy, which reflects neuronal loss and tau pathology, determines the clinical syndrome in corticobasal degeneration, as is true for other neurodegenerative disorders (Boxer et al., 2006; Josephs et al., 2008; Whitwell et al., 2010).”
BackgroundCorticobasal degeneration: a pathologically distinct 4R tauopathy
Kouri, N., Whitwell, J. L., Josephs, K. A., Rademakers, R., & Dickson, D. W. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.43 · Cited by 246
Self-citationVoxel-based morphometry in autopsy proven PSP and CBD
Josephs, K. A., Whitwell, J. L., Dickson, D. W., Boeve, B. F., Knopman, D. S., Petersen, R. C., Parisi, J. E., & Jack, C. R. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.09.019 · Cited by 234 · cited 1×
“…for clinical heterogeneity The anatomical distribution of brain atrophy, which reflects neuronal loss and tau pathology, determines the clinical syndrome in corticobasal degeneration, as is true for other neurodegenerative disorders (Boxer et al., 2006; Josephs et al., 2008; Whitwell et al., 2010).”
BackgroundSelf-citationIshizawa, K., & Dickson, D. W. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.6.647 · Cited by 209 · cited 1×
“Regions of interest were chosen based on their known involvement in corticobasal degeneration and progressive supranuclear palsy (Ishizawa and Dickson, 2001).”
BackgroundSelf-citationGröschel, K., Hauser, T.-K., Luft, A., Patronas, N., Dichgans, J., Litvan, I., & Schulz, J. B. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2003.09.070 · Cited by 125
Self-citation
Cited by
Tau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628
Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies
Rawat, P., Sehar, U., Bisht, J., Selman, A., Culberson, J., & Reddy, P. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112841 · Cited by 509
“Tau protein is considered to be a main key factor in CBD pathology and is characterized by the deposition of insoluble tau enriched in the (4R tau) fourrepeat [165,166].”
BackgroundAhmed, Z., Cooper, J., Murray, T. K., Garn, K., McNaughton, E., Clarke, H., Parhizkar, S., Ward, M. A., Cavallini, A., Jackson, S., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1254-6 · Cited by 464
Mechanisms of secretion and spreading of pathological tau protein
Brunello, C. A., Merezhko, M., Uronen, R.-L., & Huttunen, H. J. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03349-1 · Cited by 304
Kouri, N., Ross, O. A., Dombroski, B., Younkin, C. S., Serie, D. J., Soto-Ortolaza, A., Baker, M., Finch, N. C. A., Yoon, H., Kim, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms8247 · Cited by 239
“Furthermore, autopsy-confirmed CBD cases can often present with several different clinical syndromes 3 , which are frequently associated with other underlying neurodegenerative disorders such as progressive supranuclear palsy (PSP), Alzheimer’s disease (AD), and frontotemporal dementia (FTD) 4 .”
Self-citation
Metadata
- Authors
- Kouri, N., Murray, M. E., Hassan, A., Rademakers, R., Uitti, R. J., Boeve, B. F., Graff-Radford, N. R., Wszolek, Z. K., Litvan, I., Josephs, K. A., & Dickson, D. W.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-09-20
- Volume
- 134
- Issue
- 11
- Pages
- 3264-3275
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2143195814
- Cited by
- 134
- References
- 12
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.